Merck & Co Inc (MRK)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 43% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+67% over the past year+6
- 52-week positionAbove the midpoint of its 52-week range+9
- QualityRich valuation (P/E 113)-2
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is earnings, with the upcoming Q3 report and expectations of a decline driving near-term attention. Continuation likelihood is moderate (~40-50%), as the setup hinges on the actual print rather than a durable trend. Informational only — not financial advice.
- Summit Expands Ivonescimab Development Into Biliary Tract CancerYahoo · 2026-10-22
- JNJ Stock Has a New Growth Story, but One Business Needs to Catch UpYahoo · 2026-10-22
- Earnings Preview: Merck (MRK) Q3 Earnings Expected to DeclineYahoo · 2026-10-22
- Was There Any Sign Merck Stock Would Run?Yahoo · 2026-10-22
- Is Johnson & Johnson Stock Ready For A MedTech Stall?Yahoo · 2026-10-22
Any AI summary is an interpretation of public news, not advice or a price target.